-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $65

Benzinga·05/15/2025 18:10:50
Listen to the news
Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $80 to $65.